BRPI0923497A2 - derivados de piridazinona - Google Patents

derivados de piridazinona

Info

Publication number: BRPI0923497A2
Authority: BR; Brazil
Prior art keywords: pyridazinone derivatives; pyridazinone; derivatives
Prior art date: 2008-12-23

Application number

BRPI0923497A

Other languages

English (en)

Inventor

Blaukat Andree

Dorsch Dieter

Stieber Frank

Schadt Oliver

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-23

Filing date

2009-11-24

Publication date

2019-09-24

2009-11-24 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2019-09-24 Publication of BRPI0923497A2 publication Critical patent/BRPI0923497A2/pt

Links

AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Immunology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Inorganic Chemistry (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI0923497A 2008-12-23 2009-11-24 derivados de piridazinona BRPI0923497A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102008062826A DE102008062826A1 (de)	2008-12-23	2008-12-23	Pyridazinonderivate
PCT/EP2009/008360 WO2010072296A1 (de)	2008-12-23	2009-11-24	Pyridazinonderivate

Publications (1)

Publication Number	Publication Date
BRPI0923497A2 true BRPI0923497A2 (pt)	2019-09-24

Family

ID=41628227

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0923497A BRPI0923497A2 (pt)	2008-12-23	2009-11-24	derivados de piridazinona

Country Status (22)

Country	Link
US (1)	US8637518B2 (pt)
EP (1)	EP2367815B1 (pt)
JP (1)	JP5592395B2 (pt)
KR (1)	KR20110098854A (pt)
CN (1)	CN102264727B (pt)
AR (1)	AR074688A1 (pt)
AU (1)	AU2009331991B2 (pt)
BR (1)	BRPI0923497A2 (pt)
CA (1)	CA2747863C (pt)
CY (1)	CY1116191T1 (pt)
DE (1)	DE102008062826A1 (pt)
DK (1)	DK2367815T3 (pt)
EA (1)	EA201100966A1 (pt)
ES (1)	ES2532139T3 (pt)
HR (1)	HRP20150375T1 (pt)
HU (1)	HUE025138T2 (pt)
MX (1)	MX2011006652A (pt)
PL (1)	PL2367815T3 (pt)
PT (1)	PT2367815E (pt)
SI (1)	SI2367815T1 (pt)
WO (1)	WO2010072296A1 (pt)
ZA (1)	ZA201105440B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102009003954A1 (de) *	2009-01-07	2010-07-08	Merck Patent Gmbh	Pyridazinonderivate
WO2014080291A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en)	2012-11-21	2015-07-07	Zenith Epigenetics Corp.	Cyclic amines as bromodomain inhibitors
US9271978B2 (en)	2012-12-21	2016-03-01	Zenith Epigenetics Corp.	Heterocyclic compounds as bromodomain inhibitors
HUE032863T2 (en) *	2013-02-07	2017-11-28	Merck Patent Gmbh	Piridazinonamid derivatives
WO2015004533A2 (en)	2013-06-21	2015-01-15	Zenith Epigenetics Corp.	Novel substituted bicyclic compounds as bromodomain inhibitors
SG11201510409QA (en)	2013-06-21	2016-01-28	Zenith Epigenetics Corp	Novel bicyclic bromodomain inhibitors
AU2014298051B2 (en)	2013-07-31	2018-11-15	Zenith Epigenetics Ltd.	Novel quinazolinones as bromodomain inhibitors
WO2016087936A1 (en)	2014-12-01	2016-06-09	Zenith Epigenetics Corp.	Substituted pyridinones as bromodomain inhibitors
WO2016087942A1 (en)	2014-12-01	2016-06-09	Zenith Epigenetics Corp.	Substituted pyridines as bromodomain inhibitors
CN107207474B (zh)	2014-12-11	2021-05-07	恒翼生物医药科技(上海)有限公司	被取代的杂环作为溴结构域抑制剂
CA2966450A1 (en)	2014-12-17	2016-06-23	Olesya KHARENKO	Inhibitors of bromodomains
WO2018077227A1 (zh) *	2016-10-27	2018-05-03	福建广生堂药业股份有限公司	作为c-MET抑制剂的吡啶酮类化合物
EA039713B1 (ru) *	2018-04-26	2022-03-03	Фуцзянь Косантер Фармасьютикал Ко., Лтд.	Кристаллическая форма ингибитора c-met, его солевая форма и способ их получения
CN108752322A (zh)	2018-09-12	2018-11-06	广州新民培林医药科技有限公司	一种新型Tepotinib衍生物和制备方法及其在抗肿瘤药物中的应用
IL286481B2 (en) *	2019-03-20	2025-12-01	Goldfinch Bio Inc	Pyridazinones and methods of use thereof
WO2022063869A2 (en) *	2020-09-24	2022-03-31	Merck Patent Gmbh	Compounds for the treatment of viral infections
CN114736191B (zh) *	2022-04-01	2023-08-08	上海工程技术大学	特普替尼中间体及其制备方法和应用
CN115583939A (zh) *	2022-11-04	2023-01-10	苏州莱安医药化学技术有限公司	一种特泊替尼中间体的合成方法
JP2025538556A (ja) *	2022-11-22	2025-11-28	イノキュアセラピューティクス，インコーポレイテッド	Ｃｍｅｔタンパク質を分解するための分解剤、およびそれを含む薬学的組成物
CN116768868B (zh) *	2023-08-15	2023-12-08	云南省药物研究所	一种哒嗪酮硫代衍生物及其制备方法和应用
CN118084871B (zh) *	2024-04-29	2024-07-09	中国药科大学	一种靶向降解c-Met蛋白的化合物及其制法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5795964A (en)	1980-12-04	1982-06-15	Morishita Seiyaku Kk	Preparation of 2-substituted-3(2h)-pyridazinone derivative
US4397854A (en)	1981-05-14	1983-08-09	Warner-Lambert Company	Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
AU691673B2 (en)	1994-11-14	1998-05-21	Dow Agrosciences Llc	Pyridazinones and their use as fungicides
US5635494A (en)	1995-04-21	1997-06-03	Rohm And Haas Company	Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
DE19604388A1 (de)	1996-02-07	1997-08-14	Merck Patent Gmbh	Arylalkyl-diazinone
WO1997030035A1 (en)	1996-02-13	1997-08-21	Zeneca Limited	Quinazoline derivatives as vegf inhibitors
ES2169355T3 (es)	1996-03-05	2002-07-01	Astrazeneca Ab	Derivados de 4-anilinoquinazolina.
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
GB9714249D0 (en)	1997-07-08	1997-09-10	Angiogene Pharm Ltd	Vascular damaging agents
EP2017266A1 (en)	1997-11-19	2009-01-21	Kowa Co., Ltd.	Pyridazine derivatives and medicines containing the same as effective ingredients
TWI241295B (en)	1998-03-02	2005-10-11	Kowa Co	Pyridazine derivative and medicine containing the same as effect component
GB9900334D0 (en)	1999-01-07	1999-02-24	Angiogene Pharm Ltd	Tricylic vascular damaging agents
GB9900752D0 (en)	1999-01-15	1999-03-03	Angiogene Pharm Ltd	Benzimidazole vascular damaging agents
IL152682A0 (en)	2000-05-31	2003-06-24	Astrazeneca Ab	Indole derivatives with vascular damaging activity
BR0112224A (pt)	2000-07-07	2003-06-10	Angiogene Pharm Ltd	Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
HUP0301742A3 (en)	2000-07-07	2005-08-29	Angiogene Pharm Ltd	Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
US20040259863A1 (en)	2001-10-31	2004-12-23	Hans-Michael Eggenweiler	Type 4 phosphodiesterase inhibitors and uses thereof
DE102005042742A1 (de) *	2005-09-02	2007-03-08	Schering Ag	Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102005055354A1 (de)	2005-11-21	2007-10-31	Merck Patent Gmbh	Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
DE102005055355A1 (de)	2005-11-21	2007-10-31	Merck Patent Gmbh	3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
DE102005057924A1 (de)	2005-12-05	2007-06-06	Merck Patent Gmbh	Pyridazinonderivate
DE102006037478A1 (de) *	2006-08-10	2008-02-14	Merck Patent Gmbh	2-(Heterocyclylbenzyl)-pyridazinonderivate
GB0619753D0 (en)	2006-10-06	2006-11-15	Chroma Therapeutics Ltd	Enzyme inhibitors
DE102007025718A1 (de)	2007-06-01	2008-12-04	Merck Patent Gmbh	Pyridazinonderivate
DE102007025717A1 (de) *	2007-06-01	2008-12-11	Merck Patent Gmbh	Arylether-pyridazinonderivate
DE102007032507A1 (de) *	2007-07-12	2009-04-02	Merck Patent Gmbh	Pyridazinonderivate
DE102007061963A1 (de) *	2007-12-21	2009-06-25	Merck Patent Gmbh	Pyridazinonderivate
MX2011006682A (es) *	2008-12-22	2011-07-13	Merck Patent Gmbh	Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirim idin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion.
US20120028988A1 (en) *	2009-03-30	2012-02-02	Sumitomo Chemical Company, Limited	Use of pyridazinone compound for control of harmful arthropod pests

2008
- 2008-12-23 DE DE102008062826A patent/DE102008062826A1/de not_active Withdrawn
2009
- 2009-11-24 CA CA2747863A patent/CA2747863C/en active Active
- 2009-11-24 CN CN200980152038.8A patent/CN102264727B/zh not_active Expired - Fee Related
- 2009-11-24 WO PCT/EP2009/008360 patent/WO2010072296A1/de not_active Ceased
- 2009-11-24 BR BRPI0923497A patent/BRPI0923497A2/pt not_active IP Right Cessation
- 2009-11-24 PL PL09759895T patent/PL2367815T3/pl unknown
- 2009-11-24 DK DK09759895T patent/DK2367815T3/en active
- 2009-11-24 JP JP2011542689A patent/JP5592395B2/ja not_active Expired - Fee Related
- 2009-11-24 US US13/141,400 patent/US8637518B2/en not_active Expired - Fee Related
- 2009-11-24 EP EP09759895.7A patent/EP2367815B1/de active Active
- 2009-11-24 MX MX2011006652A patent/MX2011006652A/es not_active Application Discontinuation
- 2009-11-24 KR KR1020117017357A patent/KR20110098854A/ko not_active Withdrawn
- 2009-11-24 HU HUE09759895A patent/HUE025138T2/en unknown
- 2009-11-24 SI SI200931166T patent/SI2367815T1/sl unknown
- 2009-11-24 ES ES09759895.7T patent/ES2532139T3/es active Active
- 2009-11-24 HR HRP20150375TT patent/HRP20150375T1/hr unknown
- 2009-11-24 EA EA201100966A patent/EA201100966A1/ru unknown
- 2009-11-24 AU AU2009331991A patent/AU2009331991B2/en not_active Ceased
- 2009-11-24 PT PT97598957T patent/PT2367815E/pt unknown
- 2009-12-16 AR ARP090104911A patent/AR074688A1/es unknown
2011
- 2011-07-22 ZA ZA2011/05440A patent/ZA201105440B/en unknown
2015
- 2015-04-09 CY CY20151100345T patent/CY1116191T1/el unknown

Also Published As

Publication number	Publication date
ES2532139T3 (es)	2015-03-24
MX2011006652A (es)	2011-07-12
JP5592395B2 (ja)	2014-09-17
ZA201105440B (en)	2012-03-28
EP2367815A1 (de)	2011-09-28
DE102008062826A1 (de)	2010-07-01
PL2367815T3 (pl)	2015-04-30
CA2747863A1 (en)	2010-07-01
AU2009331991B2 (en)	2015-10-22
KR20110098854A (ko)	2011-09-01
SI2367815T1 (sl)	2015-05-29
PT2367815E (pt)	2015-02-20
CY1116191T1 (el)	2017-02-08
AR074688A1 (es)	2011-02-02
US20110257181A1 (en)	2011-10-20
US8637518B2 (en)	2014-01-28
DK2367815T3 (en)	2015-03-09
HRP20150375T1 (hr)	2015-05-22
AU2009331991A1 (en)	2011-08-11
EP2367815B1 (de)	2015-01-14
HUE025138T2 (en)	2016-03-29
JP2012513418A (ja)	2012-06-14
CA2747863C (en)	2016-08-23
EA201100966A1 (ru)	2012-01-30
WO2010072296A1 (de)	2010-07-01
CN102264727B (zh)	2014-11-05
CN102264727A (zh)	2011-11-30

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
CY2022017I1 (el)	2023-01-05	Παραγωγα πυριδαζινονης
BRPI0812247A2 (pt)	2015-06-16	Derivados de piridazinona
BRPI0821743A2 (pt)	2015-09-22	derivados de piridazinona
BRPI0906436A2 (pt)	2015-07-14	Derivados de ftalazinona
DK2308877T3 (da)	2014-04-22	Imidazopyridin-2-on-derivater
BRPI0820112A2 (pt)	2015-05-05	Derivados de isoxazol-piridina
BRPI0809992A2 (pt)	2014-10-14	Derivados de pirrolopirimidina
BRPI0820113A2 (pt)	2015-05-05	Derivados de isoxazolo-piridazina
BRPI0915064A2 (pt)	2015-10-27	derivados de qunoxalinadiona
BRPI0907435A2 (pt)	2015-07-14	Derivados de 5-flúor pirimidina
BRPI0911161A2 (pt)	2015-10-06	derivado de piridazinona
EP2376493A4 (en)	2012-05-30	DIHYDROPYRIMIDOPYRIMIDINDERIVAT
EP2380877A4 (en)	2012-06-27	PYRIDINE-3-CARBONSÄUREAMIDDERIVAT
BRPI0812155A2 (pt)	2019-09-24	derivados de espiroindolinona
BRPI0817935A2 (pt)	2015-04-07	Derivados de biarila
BRPI0913832A2 (pt)	2015-10-20	derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0813836A2 (pt)	2015-01-06	Derivados pirazólicos
BRPI0814236A2 (pt)	2015-01-06	Derivados de quinazolinamida
BRPI0812518A2 (pt)	2015-03-31	Derivados de indazolamida
BRPI0820649A2 (pt)	2015-06-16	Derivados de isoxazalo-pirazina
EP2336132A4 (en)	2012-03-21	MORPHOLINPURINDERIVAT
PT2367815E (pt)	2015-02-20	Derivados de piridazinona
DK2152370T3 (da)	2011-08-15	Aryletherpyridazinonderivater
DK2275414T3 (da)	2015-06-22	Cyclopentylacrylamidderivat
ATE545635T1 (de)	2012-03-15	Substituierte n-oxidpyrazinderivate